That's a very political response, Mr. Chair. I appreciate that.
I did want to point out, too, that recently we had three witnesses who wrote “Pharmacare 2020”, and they actually came as individuals. That's just to the point of Mr. Kang about how the people come.... I don't think that's as important as what they contribute to this study, and I want to thank all the witnesses for being here today, because one of the things....
We might as well talk about those other witnesses. What I was worried about with regard to their testimony is that they seemed to be leaning towards how perhaps the government should be working towards monopolizing a pharmacare program. I am concerned about anti-competition and less choice for individuals. I come from a union town in Oshawa, and one of the things with collective bargaining is that they do manage to get a really great health care program out of it.
As for some of the testimony we've heard in the past, I think it's good that it's balanced, and I'd really like to question you a little deeper with regard to the pCPA. I think it was Mr. Palmer who said that it has been a success. You're saying that half a billion dollars has already been saved. I believe it was Mr. Dempster who said that there have been about 100 medicines finished through that. How many medicines are out there to go through?
The backlog you mentioned was significant. If we were able to get through all the medicines that are out there—there must be thousands—what kinds of savings do you think we could get out of that? I know that I'm asking you to pick it out of the air, but compared to the percentage that's out there, could we find out?